Survodutide 2805997-46-8
Survodutide (CAS No. 2805997-46-8), also known by its research name BI-456906, is a synthetic long-acting peptide designed as a dual agonist of the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R). Unlike many dual-agonists based on oxyntomodulin, Survodutide is a glucagon analog engineered for extended half-life via albumin binding.
Key Features & Advantages
Dual GLP-1R / GCGR Activation
Survodutide strongly activates both GLP-1 and glucagon receptors with high potency (EC₅₀ in the sub-nanomolar range) in cell-based assays.
This dual mechanism offers a balanced metabolic effect: stimulating glucose-dependent insulin secretion (via GLP-1R) and increasing energy expenditure as well as fat utilization (via GCGR).
Long-Acting Design via Albumin Binding
The peptide is modified with a C18 diacid fatty chain attached via a hydrophilic linker, which significantly extends its half-life by promoting strong binding to serum albumin.
This modification enables a prolonged in vivo duration, making it more suitable for chronic metabolic research.
High Proteolytic Stability
Survodutide includes a non-canonical amino acid (1-aminocyclobutane-1-carboxylic acid, “Ac4c”) at position 2, which protects it from degradation by dipeptidyl peptidase-4 (DPP-4).
It also has C-terminal amidation, further enhancing its stability.
Learn about the latest products in the https://www.sxdpeptidesindustry.com/products.html
